Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Reports Positive Top-Line Preliminary Results in First Patient in Diverticulosis Pilot TrialJanuary 29, 2020

Decreased Size of Diverticula, Indications of Healing and Normalization of Bowel Movements Observed in the Initial Patient

Emmaus Life Sciences Expresses Concerns Over Inaccuracies in Draft Report Issued by ICER (Institute for Clinical and Economic Review)January 27, 2020

To the Detriment of the Sickle Cell Disease Community, the Draft Report Does Not Accurately Reflect or Interpret the Original Clinical Data and Related Efficacy and Safety of L-Glutamine Validated and Approved by the FDA

Emmaus Life Sciences Announces a New Adherence Program for Its Sickle Cell Disease PatientsJanuary 06, 2020

Implementing the Program in Collaboration with US Bioservices, an AmerisourceBergen Specialty Pharmacy, Will Drive Increased Compliance with Clinicians Recommended Treatment Programs and Provides an Unprecedented Resource for Patients with Sickle Cell Disease

Emmaus Life Sciences Announces First Purchase Order from its Partnership with taiba Healthcare Press ReleaseDecember 31, 2019

Emmaus Life Sciences, Inc. today reported that it received the initial purchase order relating to taiba Healthcare’s early access program for Endari®.

Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) RegionDecember 23, 2019

Emmaus Life Sciences, Inc., today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare’s early access program for Endari® (L-glutamine oral powder) in certain countries in the Middle East and North Africa (MENA) region.